)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
PepGen (PEPG) investor relations material
PepGen Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Discontinued PGN-EDO51 for Duchenne muscular dystrophy after failing to achieve target dystrophin levels; all DMD-related R&D activities wound down.
Focus shifted to PGN-EDODM1 for myotonic dystrophy type 1, with ongoing Phase 1 and Phase 2 trials and positive initial safety and splicing correction data.
Completed dosing in the 15 mg/kg cohort of the FREEDOM Phase 1 trial for DM1; topline data expected early Q4 2025.
Transitioning clinical sites to the FREEDOM2 Phase 2 multiple ascending dose trial, with initial results from the 5 mg/kg cohort anticipated in Q1 2026.
Appointed a new Chief Technology Officer in May 2025, bringing extensive experience in product and process development.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $74.7 million as of June 30, 2025, expected to fund operations into Q2 2026.
Net loss for the six months ended June 30, 2025, was $53.3 million; Q2 2025 net loss was $23.1 million ($0.70 per share), down from $28.3 million in Q2 2024.
Research and development expenses were $43.8 million for the first half of 2025, with Q2 2025 R&D at $18.4 million, down from $25.1 million year-over-year.
General and administrative expenses were $11.5 million for the first half of 2025, with Q2 2025 at $5.5 million, nearly flat year-over-year.
No revenue generated from product sales to date; all funding from equity offerings and financings.
Outlook and guidance
Existing cash and equivalents expected to fund operations into Q2 2026; additional capital will be required to continue operations beyond that point.
Topline data from the 15 mg/kg cohort of the FREEDOM trial expected in early Q4 2025; initial results from the 5 mg/kg cohort of the FREEDOM2 trial anticipated in Q1 2026.
Focused on advancing PGN-EDODM1 through ongoing and planned clinical trials, with key data readouts expected in late 2025 and early 2026.
Expenses and operating losses expected to continue as clinical and preclinical programs progress.
Explain the rationale to conclude FREEDOM with 15 mg/kg cohort.
Assess the impact of Kasra Kasraian's appointment.
How will PepGen fund operations beyond Q2 2026?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next PepGen earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
PepGen Inc. is a biotechnology company focused on developing nucleic acid-based therapies for neuromuscular and rare genetic diseases. The company specializes in peptide-conjugated oligonucleotide therapeutics designed to enhance drug delivery and effectiveness. Its research and development efforts target conditions such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage